HLHui Liu

Hui Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Lina Hu

    State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252059, China

    1 shared publication
  • Qing-Kun Shen

    Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin 133002, China

    1 shared publication
  • Shiben Wang

    National Key Laboratory of Macromolecular Drug Development and Manufacturing, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, 1 Hunan Street, Liaocheng 252059, China

    1 shared publication
  • Yalan Wang

    Key Laboratory of Natural Medicines of the Changbai Mountain, Yanbian University, Ministry of Education, Yanji 133002, China

    1 shared publication
  • Zhe-Shan Quan

    Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin 133002, China

    1 shared publication
  • Zheng Liu

    School of Medicine, Foshan University, Foshan 528000, China

    1 shared publication

Latest Publications

  • Open Access

    Design, Synthesis, and Biological Evaluation of Novel Morpholine–Coumarin Derivatives for Inflammation-Associated Depression

    by Hui Liu, Lina Hu, Yalan Wang, Zheshan Quan, Zheng Liu, Shiben Wang, Qingkun Shen

    The tryptophan–kynurenine pathway, mediated by indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), is critically involved in the pathogenesis of depression. A series of novel morpholine–coumarin derivatives were designed and synthesized as dual IDO1/TDO inhibitors. Through in vitro enzyme screening, compound 14d exhibited potent inhibitory activity with IC50 values of 0.34 µM and 0.75 µM, respectively. In lipopolysaccharide (LPS)-stimulated BV2 microglial cells, 14d downregulated IDO1/TDO expression, suppressed pro-inflammatory cytokines (IL-1β, COX-2, iNOS, TNF-α), and upregulated the anti-inflammatory cytokine IL-10. In an LPS-induced acute depressive mouse model established in C57BL/6 mice, intraperitoneal administration of 14d (20 mg/kg) significantly reduced immobility time in the forced swim and tail suspension tests, without affecting spontaneous locomotor activity. Mechanistic studies revealed that 14d inhibited microglial activation in the hippocampal dentate gyrus, reduced cerebral kynurenine levels, increased serotonin content, and upregulated BDNF/PKA signaling. Molecular docking further predicted the binding interactions of 14d with the active sites of IDO1 and TDO. These findings suggest that 14d represents a promising dual IDO1/TDO inhibitor lead compound for the treatment of inflammation-associated depression through modulation of the kynurenine pathway and neuroinflammatory responses.